Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?

Author(s): Maciej Banach, Manfredi Rizzo, Milan Obradovic, Giuseppe Montalto, Jacek Rysz, Dimitri P. Mikhailidis and Esma R. Isenovic

Volume 19, Issue 21, 2013

Page: [3869 - 3877] Pages: 9

DOI: 10.2174/13816128113199990303

conference banner
Abstract

Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins.

We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved.

Keywords: Cardiovascular diseases, hyperlipidemia, low-density lipoprotein, low-density lipoprotein receptor, proprotein convertase subtilisin/ kexin 9, statins.


© 2024 Bentham Science Publishers | Privacy Policy